Common diabetes drug not linked to short-term risk of pancreatic cancer
“Our research shows that short-term use of DPP-4 inhibitors in older diabetes patients does not increase their risk for pancreatic cancer,” said John Buse, MD, PhD, director of the Diabetes Care Center at UNC and co-author of the paper in the current issue of the journal Diabetes, Obesity and Metabolism. “However, we just cannot address the long-term safety, yet. There are just not enough people who have taken the drug for many years.” DPP-4 inhibitors came on the market in 2006. Since then, these drugs have become some of the most commonly prescribed diabetes medications, primarily because they often cause fewer side effects compared to other diabetes treatments…